Skip to main content

Table 2 Response of neoadjuvant chemotherapy and surgery resection rate in the two groups (N = 248)

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

  XELOX group
(N = 159)
DOS group
(N = 89)
P
Response evaluation    0.823
 CR 2 (1.2) 1 (1.1)  
 PR 53 (33.3) 33 (37.0)  
 SD 87 (54.7) 46 (51.6)  
 PD 14 (8.9) 9 (10.3)  
 Not assessable 3* (1.9) 0 (0)  
 RR (CR plus PR) 55 (34.5) 34 (38.1) 0.569
 DCR (CR plus RR plus SD) 142 (89.2) 80 (89.7) 0.886
Patients received surgery    0.4850
 Radical surgery 111 (69.8) 65 (73.0)  
 Non-radical surgery 48 (30.2) 34 (27.0)  
  1. *There patients in XELOX group did not have response evaluation because of acute stomach perforation after the first regimen of chemotherapy